AIM: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in human ductal breast cancer. MATERIALS AND METHODS: Breast carcinomas were obtained from 82 patients. MUC1 expression and hormone receptor status were determined by immunohistochemistry of paraffin-embedded material. RESULTS: PankoMab revealed strong correlation to hormone receptor expression. DF3 showed no correlation with grading, lymph node involvement and/or estrogen receptor (ER) expression. In the subgroup of lymph node-positive and ER-negative tumors, we saw a significantly reduced DF3 staining in G3 tumors compared to G2 tumors. VU-4-H5 showed increased staining intensity in correlation with increased grading. In addition, we also identified a significantly higher expression of the VU-4-H5 epitope in lymph node-positive carcinomas compared to carcinomas without lymph node involvement. CONCLUSION: PankoMab revealed strong correlation to hormone receptor expression in ductal carcinoma of the breast. VU-4-H5 showed increased staining intensity in correlation with increased grading and lymph node involvement. PankoMab and VU-4-H5 staining could be a useful combination in ductal breast cancer prognosis by immunohistochemistry. Copyright (c) 2009 S. Karger AG, Basel.
AIM: PankoMab is a novel antibody that recognizes a tumor-specific epitope of Mucin 1 (MUC1). The aim of this study was the evaluation of PankoMab as a potential diagnostic tool and its comparison with two established antibodies against MUC1 in humanductal breast cancer. MATERIALS AND METHODS:Breast carcinomas were obtained from 82 patients. MUC1 expression and hormone receptor status were determined by immunohistochemistry of paraffin-embedded material. RESULTS: PankoMab revealed strong correlation to hormone receptor expression. DF3 showed no correlation with grading, lymph node involvement and/or estrogen receptor (ER) expression. In the subgroup of lymph node-positive and ER-negative tumors, we saw a significantly reduced DF3 staining in G3 tumors compared to G2 tumors. VU-4-H5 showed increased staining intensity in correlation with increased grading. In addition, we also identified a significantly higher expression of the VU-4-H5 epitope in lymph node-positive carcinomas compared to carcinomas without lymph node involvement. CONCLUSION: PankoMab revealed strong correlation to hormone receptor expression in ductal carcinoma of the breast. VU-4-H5 showed increased staining intensity in correlation with increased grading and lymph node involvement. PankoMab and VU-4-H5 staining could be a useful combination in ductal breast cancer prognosis by immunohistochemistry. Copyright (c) 2009 S. Karger AG, Basel.
Authors: Catharina Steentoft; Katrine T Schjoldager; Emiliano Cló; Ulla Mandel; Steven B Levery; Johannes W Pedersen; Knud Jensen; Ola Blixt; Henrik Clausen Journal: Glycoconj J Date: 2010-08-19 Impact factor: 2.916
Authors: Sabine Heublein; Klaus Friese; Bernd Kost; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Doris Mayr; Udo Jeschke; Aurelia Vattai Journal: J Cancer Res Clin Oncol Date: 2018-07-30 Impact factor: 4.553
Authors: Klaus Friese; Bernd Kost; Aurelia Vattai; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Udo Jeschke; Sabine Heublein Journal: J Cancer Res Clin Oncol Date: 2017-09-18 Impact factor: 4.553
Authors: Ieva Bagdonaite; Emil M H Pallesen; Mathias I Nielsen; Eric P Bennett; Hans H Wandall Journal: Adv Exp Med Biol Date: 2021 Impact factor: 3.650